ViiV Healthcare seems to fit your puzzle well. HIV joint venture between GSK (76.5%), PFE (13.5%) and Shionogi (10% who joined in 2012). Checks many of the boxes with HIV, US sales force and Hong Kong Exchange connection.
https://en.m.wikipedia.org/wiki/ViiV_Healthcare
Please do your own due diligence. All my posts and comments are not to be considered investment advice.